Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2
about
Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneityThe chemical biology of protein phosphorylationCrystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252aCrystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 proteinStructural basis for Chk1 inhibition by UCN-01Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibitionStructural and Functional Characterization of the Human Protein Kinase ASK1Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitorsAuto-activation mechanism of the Mycobacterium tuberculosis PknB receptor Ser/Thr kinaseDiscovery of a Potential Allosteric Ligand Binding Site in CDK2A Novel Approach to the Discovery of Small-Molecule Ligands of CDK2Anticancer compound plumbagin and its molecular targets: a structural insight into the inhibitory mechanisms using computational approachesComprehensive structural and functional characterization of the human kinome by protein structure modeling and ligand virtual screening.Cell cycle-regulated proteolysis of mitotic target proteins.In silico study of fucoxanthin as a tumor cytotoxic agentStaurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling.Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3).The protein kinase C inhibitor bisindolyl maleimide 2 binds with reversed orientations to different conformations of protein kinase A.Indolocarbazole natural products: occurrence, biosynthesis, and biological activity.Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screeningSelectivity and potency of cyclin-dependent kinase inhibitors.Molecular Dynamics Simulations and Classical Multidimensional Scaling Unveil New Metastable States in the Conformational Landscape of CDK2.A Rising Cancer Prevention Target of RSK2 in Human Skin Cancer.High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile.The marine natural-derived inhibitors of glycogen synthase kinase-3beta phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling.Natural products as kinase inhibitors.Personalized Medicine and Resurrected Hopes for the Management of Alzheimer's Disease: A Modular Approach Based on GSK-3β Inhibitors.Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases.Purification, characterization, and kinetic mechanism of cyclin D1. CDK4, a major target for cell cycle regulation.Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).Mitogen-activated protein kinases interacting kinases are autoinhibited by a reprogrammed activation segment.Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors.Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors.The three-dimensional structure of the ZAP-70 kinase domain in complex with staurosporine: implications for the design of selective inhibitors.A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.Performance of the MM/GBSA scoring using a binding site hydrogen bond network-based frame selection: the protein kinase case.An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.A liquid chromatography/mass spectrometry-based method for the selection of ATP competitive kinase inhibitors.Computational evaluation of some indenopyrazole derivatives as anticancer compounds; application of QSAR and docking methodologies.
P2860
Q24539769-834B550F-0911-4AAD-9E8F-27A7220E9E48Q24620636-A246F76E-3F71-4733-974D-ECB114AA1977Q24647566-6057FDB2-114C-4E84-B7E2-D1710819263BQ27631578-57A8573A-D4AB-4716-87BA-0B0B9B64F43AQ27639676-7F9C96E2-933C-468A-BF75-D5DBD63FE75AQ27641764-13A940A0-03A4-49F6-918A-61B2B28371BBQ27648785-9B7DA1DB-C144-44D8-B162-CAD52F4AF7CBQ27648916-2E113A53-8C72-4013-BA75-3C50C805DA86Q27652901-F7CD0273-AD07-4CD7-B6E0-3E6C142BA401Q27666837-C0ED4DDB-1B13-40E4-A37D-AE7869156DAAQ27671549-1C086D4B-4C4F-4BFF-BFEB-4B7DFAE5DC2CQ28540187-E413188F-4707-4F97-9C2A-1B550075A0C9Q30393891-7E70AD6E-7614-4B57-BEFA-B69CE9358172Q30454298-F9BC2778-FAF8-4C59-930C-F75DA86B28F3Q31049147-F622EE2A-2DFC-4A8D-BCA5-0E2D17C982A2Q33493022-240EA328-B96D-49D6-8305-66C9184FCC40Q34270442-6E995B4B-FA0C-495D-BBFD-8E4A15E453E3Q34302668-1EF9A087-C3DD-4D91-A0C2-1A06B3599786Q34583547-0DD103F4-F953-485B-92B8-694730CEDDE1Q34625383-064525DD-7448-4D71-9A4A-ABADABB03123Q34651981-B09F8AA8-BE3E-4BE5-9B26-A5C81A7D9107Q35995752-CE1A2205-AAD9-4E10-A29A-7A36BAF67B19Q37068772-DBA745ED-2A04-45F1-B938-4C3D6C74CD75Q37255085-E29123E5-3B9A-4B7D-9814-58A72157A80EQ37345648-0667A20E-5B59-448C-98F4-69C10D1A1978Q37974484-3F878486-4346-47E8-90F4-137F53E55ED6Q38608683-94300BDE-A102-45C1-83C0-62993BB16E52Q40290597-8A4F90F1-DA15-428C-AE55-683BF62B14A9Q40918567-8F14B661-F196-477B-B327-71A0E2E76483Q41005486-BE2E37B9-E249-4DDE-AAFD-A2545498B0A3Q42716844-EEF3B8DB-6F38-4BB3-9FB3-FC661C26BF33Q42763653-91998488-C71C-4A9F-A5EC-98456EE95357Q44207658-E7259F24-B2EF-48F0-80B1-203FBC08DB40Q44760560-58AF49F7-F9F6-4AD7-937D-AC3445976CD4Q45005856-A542F26D-FFF9-4C33-B926-4FF0AF442736Q45126637-5D4530F3-C5E7-4DBB-86C8-4A49D74872F1Q45188356-37602F57-4CB9-4B29-BD70-9E36106CA550Q45327842-A6853424-4BE2-44F6-9B8C-0A87C3507B67Q46644558-25690451-E14F-4D30-A809-6F851335A8CBQ46969486-3E0A6BCC-D9C3-44E4-A87F-99BF605CF776
P2860
Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2
description
1997 nî lūn-bûn
@nan
1997 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
name
Protein kinase inhibition by s ...... olecular interaction with CDK2
@ast
Protein kinase inhibition by s ...... olecular interaction with CDK2
@en
Protein kinase inhibition by s ...... olecular interaction with CDK2
@nl
type
label
Protein kinase inhibition by s ...... olecular interaction with CDK2
@ast
Protein kinase inhibition by s ...... olecular interaction with CDK2
@en
Protein kinase inhibition by s ...... olecular interaction with CDK2
@nl
prefLabel
Protein kinase inhibition by s ...... olecular interaction with CDK2
@ast
Protein kinase inhibition by s ...... olecular interaction with CDK2
@en
Protein kinase inhibition by s ...... olecular interaction with CDK2
@nl
P2093
P2860
P3181
P356
P1476
Protein kinase inhibition by s ...... olecular interaction with CDK2
@en
P2093
A M Lawrie
J A Endicott
L N Johnson
P2860
P304
P3181
P356
10.1038/NSB1097-796
P577
1997-10-01T00:00:00Z